bluebird bio Inc (NASDAQ:BLUE) insider David Davidson sold 22,000 shares of the firm’s stock in a transaction that occurred on Monday, April 2nd. The stock was sold at an average price of $167.52, for a total transaction of $3,685,440.00. The transaction was disclosed in a document filed with the SEC, which is accessible through this link.
David Davidson also recently made the following trade(s):
- On Friday, February 2nd, David Davidson sold 4,000 shares of bluebird bio stock. The stock was sold at an average price of $202.36, for a total transaction of $809,440.00.
- On Monday, January 8th, David Davidson sold 3,522 shares of bluebird bio stock. The stock was sold at an average price of $173.61, for a total transaction of $611,454.42.
NASDAQ:BLUE opened at $162.70 on Friday. bluebird bio Inc has a 12 month low of $74.45 and a 12 month high of $236.17. The company has a market capitalization of $8,652.15, a PE ratio of -21.10 and a beta of 2.16.
bluebird bio (NASDAQ:BLUE) last released its quarterly earnings results on Wednesday, February 21st. The biotechnology company reported ($2.52) EPS for the quarter, missing the Zacks’ consensus estimate of ($1.68) by ($0.84). bluebird bio had a negative net margin of 947.42% and a negative return on equity of 28.09%. The firm had revenue of $4.17 million during the quarter, compared to the consensus estimate of $7.11 million. During the same period in the prior year, the business earned ($1.88) EPS. The company’s revenue for the quarter was up 169.0% compared to the same quarter last year. sell-side analysts forecast that bluebird bio Inc will post -8.39 EPS for the current year.
Large investors have recently added to or reduced their stakes in the company. Meeder Asset Management Inc. raised its position in shares of bluebird bio by 2,110.3% in the fourth quarter. Meeder Asset Management Inc. now owns 641 shares of the biotechnology company’s stock valued at $114,000 after purchasing an additional 612 shares during the period. NuWave Investment Management LLC bought a new position in shares of bluebird bio in the fourth quarter valued at approximately $135,000. Ladenburg Thalmann Financial Services Inc. raised its position in shares of bluebird bio by 454.2% in the third quarter. Ladenburg Thalmann Financial Services Inc. now owns 992 shares of the biotechnology company’s stock valued at $136,000 after purchasing an additional 813 shares during the period. D.A. Davidson & CO. bought a new position in shares of bluebird bio in the fourth quarter valued at approximately $214,000. Finally, Quinn Opportunity Partners LLC bought a new position in shares of bluebird bio in the fourth quarter valued at approximately $232,000.
A number of analysts have issued reports on BLUE shares. BMO Capital Markets set a $215.00 target price on shares of bluebird bio and gave the company a “buy” rating in a research note on Monday, December 11th. Jefferies Group upgraded shares of bluebird bio from a “hold” rating to a “buy” rating and lifted their target price for the company from $130.00 to $211.00 in a research note on Monday, December 11th. SunTrust Banks lifted their target price on shares of bluebird bio to $223.00 and gave the company a “buy” rating in a research note on Tuesday, December 12th. BidaskClub cut shares of bluebird bio from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, January 16th. Finally, Canaccord Genuity reiterated a “buy” rating and issued a $250.00 target price on shares of bluebird bio in a research note on Thursday, February 1st. Four investment analysts have rated the stock with a sell rating, nine have given a hold rating and thirteen have given a buy rating to the company. The stock has an average rating of “Hold” and a consensus target price of $195.20.
COPYRIGHT VIOLATION NOTICE: “bluebird bio Inc (BLUE) Insider Sells $3,685,440.00 in Stock” was originally posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this piece of content on another publication, it was stolen and republished in violation of U.S. and international copyright law. The original version of this piece of content can be viewed at https://www.dispatchtribunal.com/2018/04/07/bluebird-bio-inc-blue-insider-sells-3685440-00-in-stock.html.
About bluebird bio
bluebird bio, Inc is a clinical-stage biotechnology company. The Company is focused on developing gene therapies for severe diseases and cancer. With its lentiviral-based gene therapy and gene editing capabilities, it has built an integrated product platform with various applications in these areas. The Company’s clinical programs in severe genetic diseases include its LentiGlobin product candidate to treat transfusion-dependent b-thalassemia and to treat severe sickle cell disease (SCD) and its Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD).
Receive News & Ratings for bluebird bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bluebird bio and related companies with MarketBeat.com's FREE daily email newsletter.